Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment

ConferencepositiveNeuLogiq® PlatformPositive

AI Analysis

Summary

Cumulus Neuroscience presented data at AAIC 2026 showing its NeuLogiq® Platform two-minute digital task effectively discriminates between control, MCI, and Alzheimer's dementia groups and detects blood-biomarker-defined pathology across three independent studies, supporting its use for Alzheimer's trial pre-enrichment.

Outcome Details

Two-minute digital task demonstrated clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology across three independent studies

Importance:5/10

Sentiment:

0.70

Alzheimer's diseaseDigital biomarkerDiagnostic toolAAIC 2026MCIDementia

Read the original article

Published by PR Newswire Biotech on July 15, 2026 9:11 AM

Read Original